Amicus Therapeutics (FOLD) Short Interest Ratio & Short Volume → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free FOLD Stock Alerts $10.28 +0.11 (+1.08%) (As of 04/26/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Amicus Therapeutics Short Interest DataCurrent Short Volume31,320,000 sharesPrevious Short Volume32,490,000 sharesChange Vs. Previous Month-3.60%Dollar Volume Sold Short$333.87 millionShort Interest Ratio / Days to Cover10.3Last Record DateApril 15, 2024Outstanding Shares296,176,000 sharesPercentage of Shares Shorted10.57%Today's Trading Volume1,714,709 sharesAverage Trading Volume2,662,181 sharesToday's Volume Vs. Average64% Short Selling Amicus Therapeutics ? Sign up to receive the latest short interest report for Amicus Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatFOLD Short Interest Over TimeFOLD Days to Cover Over TimeFOLD Percentage of Float Shorted Over Time Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details Amicus Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/202431,320,000 shares $333.87 million -3.6%N/A10.3 $10.66 3/31/202432,490,000 shares $382.73 million +0.3%N/A10.7 $11.78 3/15/202432,400,000 shares $371.95 million +4.8%N/A10.3 $11.48 2/29/202430,910,000 shares $396.27 million +15.4%N/A9.4 $12.82 2/15/202426,780,000 shares $374.92 million +9.8%N/A8.6 $14.00 1/31/202424,400,000 shares $303.29 million -2.6%N/A8.1 $12.43 Get the Latest News and Ratings for FOLD and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/15/202425,060,000 shares $330.29 million -2.7%N/A8.3 $13.18 12/31/202325,750,000 shares $365.39 million -4.3%N/A8.8 $14.19 12/15/202326,910,000 shares $342.30 million +11.5%N/A9.2 $12.72 11/30/202324,140,000 shares $266.02 million +6.2%N/A9.6 $11.02 11/15/202322,730,000 shares $242.30 million +0.8%N/A9.6 $10.66 10/31/202322,560,000 shares $247.48 million +0.4%N/A10 $10.97 10/15/202322,480,000 shares $234.69 million +19.1%N/A9.3 $10.44 9/30/202318,870,000 shares $229.46 million -0.2%N/A7.9 $12.16 9/15/202318,900,000 shares $247.40 million -3.8%N/A8.6 $13.09 8/31/202319,640,000 shares $251.78 million +3.1%N/A8.5 $12.82 8/15/202319,050,000 shares $247.46 million -16.6%N/A7.9 $12.99 7/31/202322,830,000 shares $310.94 million +13.3%N/A8.2 $13.62 7/15/202320,150,000 shares $270.01 million -6.5%N/A7.9 $13.40 6/30/202321,540,000 shares $270.54 million +10.0%N/A8.7 $12.56 6/15/202319,580,000 shares $253.76 million +2.4%N/A7.6 $12.96 5/31/202319,120,000 shares $215.29 million -10.2%N/A7.6 $11.26 5/15/202321,300,000 shares $238.56 million -1.1%N/A8.7 $11.20 4/30/202321,530,000 shares $248.46 million +2.2%N/A9.8 $11.54 4/15/202321,060,000 shares $240.08 million +5.4%N/A9.9 $11.40 3/31/202319,980,000 shares $221.58 million -4.3%N/A8.9 $11.09 3/15/202320,880,000 shares $238.66 million +15.4%N/A9.8 $11.43 2/28/202318,090,000 shares $238.61 million +0.2%N/A8.6 $13.19 2/15/202318,060,000 shares $236.77 million -8.1%N/A8.8 $13.11 1/31/202319,650,000 shares $256.24 million +1.5%N/A9.3 $13.04 1/15/202319,370,000 shares $248.52 million -3.8%N/A8.5 $12.83 12/30/202220,140,000 shares $245.91 million +12.6%N/A9.2 $12.21 12/15/202217,880,000 shares $216.17 million -12.0%N/A7.8 $12.09 11/30/202220,310,000 shares $245.75 million +7.6%N/A8.3 $12.10 11/15/202218,880,000 shares $220.33 million +3.4%N/A7.4 $11.67 10/31/202218,260,000 shares $182.60 million -12.1%N/A7.1 $10.00 10/15/202220,780,000 shares $220.27 million +2.3%N/A7.8 $10.60 9/30/202220,310,000 shares $212.04 million -8.5%N/A7.3 $10.44 9/15/202222,200,000 shares $243.09 million +2.5%N/A7.4 $10.95 8/31/202221,660,000 shares $243.24 million +13.2%N/A6.9 $11.23My top 100 stocks… (Ad)We recently ran an internal audit of every trade recommendation I’ve published across all my services… And let me tell ya, we found some incredible insights… For starters, we found about 100 stocks I trade really, really well.Get some cool freebies right here. FOLD Short Interest - Frequently Asked Questions What is Amicus Therapeutics' current short interest? Short interest is the volume of Amicus Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 15th, traders have sold 31,320,000 shares of FOLD short. Learn More on Amicus Therapeutics' current short interest. What is a good short interest ratio for Amicus Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. FOLD shares currently have a short interest ratio of 10.0. Learn More on Amicus Therapeutics's short interest ratio. Which institutional investors are shorting Amicus Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Amicus Therapeutics: Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Amicus Therapeutics' short interest increasing or decreasing? Amicus Therapeutics saw a decrease in short interest in April. As of April 15th, there was short interest totaling 31,320,000 shares, a decrease of 3.6% from the previous total of 32,490,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Amicus Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Amicus Therapeutics: Alkermes plc (7.99%), Madrigal Pharmaceuticals, Inc. (17.14%), Geron Co. (9.04%), BridgeBio Pharma, Inc. (10.86%), Dynavax Technologies Co. (14.17%), Ironwood Pharmaceuticals, Inc. (13.96%), Ligand Pharmaceuticals Incorporated (4.98%), MannKind Co. (13.21%), Innoviva, Inc. (18.46%), OPKO Health, Inc. (23.81%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Amicus Therapeutics stock? Short selling FOLD is an investing strategy that aims to generate trading profit from Amicus Therapeutics as its price is falling. FOLD shares are trading up $0.11 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Amicus Therapeutics? A short squeeze for Amicus Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of FOLD, which in turn drives the price of the stock up even further. How often is Amicus Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including FOLD, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Alkermes Short Interest Madrigal Pharmaceuticals Short Interest Geron Short Interest BridgeBio Pharma Short Interest Dynavax Technologies Short Interest Ironwood Pharmaceuticals Short Interest Ligand Pharmaceuticals Short Interest MannKind Short Interest Innoviva Short Interest OPKO Health Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:FOLD) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHis win rate puts Warren Buffett to shame… Investing DailyThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBiden out June 13; Kamala won’t replace him?Paradigm PressEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals